RAD51 and esophageal cancer: We next cloned the promoter and the 5′end region of RAD51 (from −1693 to +487 bp) into a luciferase reporter plasmid, pGL3-basic vector, transfected them into esophageal cancer cells, and tested the RAD51 promoter activity in response to berberine treatment.